IP Library › Granted Patent US 12,344,868
Granted Patent B2
US 12,344,868 · App. 17/271,018 · Granted Jul 1, 2025

ENPP1 polypeptides and methods of using same

Inventors: Paul Stabach (Woodbridge, CT); Demetrios Braddock (Guilford, CT)
Assignee: YALE UNIVERSITY
C12N9/14A61K38/00C07K2319/02C07K2319/30C12Y306/01009
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,868
App. No.
17/271,018
Granted
Jul 1, 2025
Kind
B2
Abstract

The present invention includes ENPP1 polypeptides with improved in vivo half-lives. The invention further provides an ENPP1 polypeptide fusion comprising an ENPP1 polypeptide fused to a Fc region of an immunoglobulin, wherein the polypeptide fusion comprises at least one point mutation.

Claims (24)

1. An ENPP1 polypeptide fusion comprising an ENPP1 polypeptide fused to a Fc region of an immunoglobulin,

wherein the ENPP1 polypeptide comprises at least one mutation selected from the group consisting of C25N, K27T, V29N, K369N, I371T, P534N, V536T, R545T, P554L, E592N, R741D, and S766N as relating to SEQ ID NO:7.

2. The polypeptide fusion of claim 1 , wherein the Fc region comprises:

(a) at least one mutation selected from the group consisting of S885N, M883Y, M883Y/S885T/T887E, and H1064K/N1065F as relating to SEQ ID NO:7, or

(b) at least one mutation selected from the group consisting of M883Y, S885N, S885T, T887E, H1064K, N1065F, E864N and L866T as relating to SEQ ID NO: 7.

3. The polypeptide fusion of claim 1 , wherein the ENPP1 polypeptide comprises at least one mutation selected from the group consisting of C25N/K27T and V29N as relating to SEQ ID NO:7.

4. The polypeptide fusion of claim 1 , wherein the ENPP1 polypeptide comprises at least the mutation K369N/I371T as relating to SEQ ID NO:7.

5. The polypeptide fusion of claim 1 , wherein the ENPP1 polypeptide comprises at least one mutation selected from the group consisting of P534N/V536T, P554L/R545T, E592N, E592N/R741D, and S766N as relating to SEQ ID NO: 7.

6. The polypeptide fusion of claim 1 , wherein the ENPP1 polypeptide comprises at least the mutation E864N/L866T as relating to SEQ ID NO:7.

7. The polypeptide fusion of claim 1 , comprising at least one mutation selected from the group consisting of C25N, K27T, V29N, C25N/K27T, K369N, I371T, K369N/I371T, P534N, V536T, R545T, P554L, E592N, R741D, S766N, P534N/V536T, P554L/R545T, E592N/R741D, E864N, L866T, E864N/L866T, M883Y, S885N, S885T, T887E, H1064K, N1065F, M883Y/S885T/T887E, H1064K/N1065F as relating to SEQ ID NO:7.

8. The polypeptide fusion of claim 1 , wherein the Fc region is of an IgG.

9. The polypeptide fusion of claim 1 , comprising at least one mutation selected from the group consisting of P534N, V536T, R545T, P554L, S766N, and E592N as relating to SEQ ID NO:7.

10. The polypeptide fusion of claim 1 , comprising at least one mutation selected from the group consisting of S766N, P534N/V536T, P554L/R545T, and E592N as relating to SEQ ID NO:7.

11. The polypeptide fusion of claim 1 , comprising at least one mutation selected from the group consisting of S885N, S766N, M883Y/S885T/T887E, E864N/L866T, P534N/V536T/H1064K/N1065F, P554L/R545T, S766N/H1064K/N1065F, E592N/H1064K/N1065F, and P534N/V536T/M883Y/S885T/T887E as relating to SEQ ID NO:7.

12. An ENPP1 polypeptide fusion comprising an ENPP1 polypeptide and a Fc region of an immunoglobulin, wherein at least two of the following apply:

(a) the polypeptide fusion comprises mutations M883Y, S885T, and T887E as relating to SEQ ID NO:7;

(b) the polypeptide fusion comprises mutations P534N, V536T, M883Y, S885T, and T887E as relating to SEQ ID NO:7;

(c) the polypeptide fusion comprises mutations E592N, H1064K, and N1065F as relating to SEQ ID NO:7.

13. The polypeptide fusion of claim 1 , which is expressed from a CHO cell line stably transfected with human ST6 beta-galatosamide alpha-2,6-sialyltransferase (also known as ST6GAL1).

14. The polypeptide fusion of claim 1 , which is grown in a cell culture supplemented with at least one of sialic acid and N-acetylmannosamine (also known as 1,3,4-O-Bu 3 ManNAc).

15. A method of treating, reversing, or preventing progression of at least one of ossification of the posterior longitudinal ligament (OPLL) and hypophosphatemic rickets in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the polypeptide fusion of claim 1 .

16. A method of reducing or preventing progression of at least one disease selected from the group consisting of chronic kidney disease (CKD), end stage renal disease (ESRD), calcific uremic arteriolopathy (CUA), calciphylaxis, ossification of the posterior longitudinal ligament (OPLL), hypophosphatemic rickets, osteoarthritis, aging related hardening of arteries, idiopathic infantile arterial calcification (IIAC), Generalized Arterial Calcification of Infancy (GACI), and calcification of atherosclerotic plaques in a subject diagnosed with the at least one disease, the method comprising administering to the subject a therapeutically effective amount of the polypeptide fusion of claim 1 .

17. A method of reducing or preventing progression of aging related hardening of arteries in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the polypeptide fusion of claim 1 .

18. The polypeptide fusion of claim 1 , wherein the Fc region comprises at least one mutation selected from the group consisting of M883Y, S885N, S885T, T887E, H1064K, N1065F, E864N and L866T as relating to SEQ ID NO:7.

Assignments (1)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
Continuity (3)
Provisional Application 62830247 · Apr 5, 2019
Provisional Application 62725607 · Aug 31, 2018
Related Publication 20220119782A1 · Apr 21, 2022
References Cited (131)
US 5428130A · Capon et al. · 1995 [cited by applicant]
US 5968508A · Goldfine et al. · 1999 [cited by applicant]
US 6043056A · Yue et al. · 2000 [cited by applicant]
US 6358923B1 · Yue et al. · 2002 [cited by applicant]
US 7323542B2 · Balian et al. · 2008 [cited by applicant]
US 7888372B2 · Millan et al. · 2011 [cited by applicant]
US 8846603B2 · Quinn et al. · 2014 [cited by applicant]
US 9744219B2 · Braddock et al. · 2017 [cited by applicant]
US 9913881B2 · Braddock et al. · 2018 [cited by applicant]
US 10064917B2 · Braddock et al. · 2018 [cited by applicant]
US 10213483B2 · Otterlei et al. · 2019 [cited by applicant]
US 10213484B2 · Braddock et al. · 2019 [cited by applicant]
US 10493135B2 · Braddock et al. · 2019 [cited by applicant]
US 10517927B2 · Braddock et al. · 2019 [cited by applicant]
US 10583170B2 · Braddock et al. · 2020 [cited by applicant]
US 10624958B2 · Braddock et al. · 2020 [cited by applicant]
US 20030190311A1 · Dall et al. · 2003 [cited by applicant]
US 20070004913A1 · Challita-Eid et al. · 2007 [cited by applicant]
US 20070015145A1 · Woolf et al. · 2007 [cited by applicant]
US 20080273206A1 · Genge et al. · 2008 [cited by applicant]
US 20100203076A1 · Fotin-Mleczek et al. · 2010 [cited by applicant]
US 20140154774A1 · Quinn et al. · 2014 [cited by applicant]
US 20140349369A1 · Buechler et al. · 2014 [cited by applicant]
US 20140377859A1 · Quinn et al. · 2014 [cited by applicant]
US 20150024460A1 · Quinn et al. · 2015 [cited by applicant]
US 20150359858A1 · Braddock et al. · 2015 [cited by applicant]
US 20160184387A1 · Charmot et al. · 2016 [cited by applicant]
US 20160184458A1 · Heartlein · 2016 [cited by applicant]
US 20170340713A1 · Braddock et al. · 2017 [cited by applicant]
US 20170340714A1 · Braddock · 2017 [cited by examiner]
US 20170354719A1 · Braddock et al. · 2017 [cited by applicant]
CN 107109381A · 2017 [cited by applicant]
EP 3298140A1 · 2018 [cited by applicant]
JP 2005501514A · 2005 [cited by applicant]
JP 2008188015A · 2008 [cited by applicant]
JP 2018516566A · 2018 [cited by applicant]
RU 2013142583A · 2015 [cited by applicant]
RU 2016107788A · 2018 [cited by applicant]
WO 0239994A2 · 2002 [cited by applicant]
WO 02092020A2 · 2002 [cited by applicant]
WO 03040340A2 · 2003 [cited by applicant]
WO 2006135925A2 · 2006 [cited by applicant]
WO 2008105911A2 · 2008 [cited by applicant]
WO 2011113027A2 · 2011 [cited by applicant]
WO 2012125182A1 · 2012 [cited by applicant]
WO 2014126965A2 · 2014 [cited by applicant]
WO 2016100803A2 · 2016 [cited by applicant]
WO 2016187408A1 · 2016 [cited by applicant]
WO 2017087936A1 · 2017 [cited by applicant]
WO 2017191274A2 · 2017 [cited by applicant]
WO 2018027024A1 · 2018 [cited by applicant]
WO 2018157165A1 · 2018 [cited by applicant]
WO 2019217373A1 · 2019 [cited by applicant]
Genbank Accession No. XP _006144365.1, Retrieved from the Internet «https://www.ncbi.nlm.nih.gov/protein/XP_006144365.1? report=genbank&log$=protalign&blast_rank=92&RI D=X9E 1 SC3Z016», Retrieved on Feb. 20, 2024. [cited by applicant]
Dohler, et al. “Crystal structure and substrate binding mode of ectonucleotide phosphodiesterase/pyrophosphatase-3 (NPP3).” Scientific reports 8.1 (2018): 1-13. [cited by applicant]
Li, et al. “Serum phosphate concentration and incidence of stroke: a systemic review and meta-analysis.” Neurological sciences 35.12 (2014): 1877-1882. [cited by applicant]
Kassim (Clinical Advances in Hematology & Oncology vol. 14, Issue May 5, 2016 pp. 307-309). [cited by applicant]
Extended European Search Report for European Patent Application No. 20783595.0 dated Jan. 2, 2023. [cited by applicant]
Nitschke, et al. “ENPP1-Fc prevents neointima formation in generalized arterial calcification of infancy through the generation of AMP.” Experimental & Molecular Medicine 50.10 (2018): 1-12. [cited by applicant]
Albright, et al. “ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy.” Nature communications 6.1 (2015): 10006. [cited by applicant]
Mackenzie, et al. “New insights into NPP1 function: lessons from clinical and animal studies.” Bone 51.5 (2012): 961-968. [cited by applicant]
Nitschke, Y et al. “Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6.” The American Journal of Human Genetics 90.1 (2012): 25-39. [cited by applicant]
Nitschke, et al. “Generalized arterial calcification of infancy and pseudoxanthoma elasticum: two sides of the same coin.” Frontiers in genetics 3 (2012): 302. [cited by applicant]
Rutsch, et al. “Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel.” Circulation research 109.5 (2011): 578-592. [cited by applicant]
Nitschke, et al. “Inherited arterial calcification syndromes: etiologies and treatment concepts.” Current osteoporosis reports 15 (2017): 255-270. [cited by applicant]
European Supplemental Partial Search Report for European Patent Application No. 14751154.7 issued Nov. 7, 2016. [cited by applicant]
Extended European Search Report for European Patent Application No. 14751154.7 issued Feb. 16, 2017. [cited by applicant]
Extended European Search Report for European Patent Application No. 16797290.0 issued Jun. 25, 2019. [cited by applicant]
Extended European Search Report for European Patent Application No. 17837677.8 issued Mar. 24, 2020. [cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/US2017/045280 issued Dec. 26, 2017. [cited by applicant]
Mus musculus domesticus ecto-nucleotide pyrophosphatase/phosphodiesterase-1 mRNA, complete cds, GenBank J02700.2, Aug. 12, 2020 searched. [cited by applicant]
Notice of Panel Decision from Pre-Appeal Brief Review for U.S. Appl. No. 15/812,456 issued Dec. 2, 2020. [cited by applicant]
Notice of Reasons for Rejection for Japanese Patent Application No. 2017-560327 dated Mar. 30, 2020, 5 pages. [cited by applicant]
PCT International Search Report and Written Opinion for PCT International Application No. PCT/US2014/015945 issued Jul. 30, 2014. [cited by applicant]
PCT International Search Report and Written Opinion for PCT International Application No. PCT/US2016/033236 Issued Oct. 27, 2016. [cited by applicant]
Pre-Appeal Brief for U.S. Appl. No. 15/812,456, filed Oct. 16, 2020. [cited by applicant]
UniProt Accession No. O14638, ENPP3_Human, Jan. 7, 2015 [online]. [Retrieved on Jan. 19, 2017]. Retrieved from the internet <URL: http://www.uniprot.org/uniprot/O14638.txt?version=133>. [cited by applicant]
“Chronic Renal Failure: From the Perspective of Internal Medicine”, Clinical Imagiology 21(11), 2005, 1142-1149 (Partial Translation). [cited by applicant]
“Pharmacokinetic Control of Biopharmaceuticals”, Journal of Pharmaceutical Science and Technology, Japan, 2014, 27-32 (Partial Translation). [cited by applicant]
Albright , et al., “ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy”, Nat Commun. 6, 2015, 10006. [cited by applicant]
Albright , et al., “Molecular basis of purinergic signal metabolism by ectonucleotide pyrophosphatase/phosphodiesterases 4 and 1 and implications in stroke”, J Biol Chem. 289(6), 2014, 3294-3306. [cited by applicant]
Albright , et al., “NPP4 is a procoagulant enzyme on the surface of vascular endothelium”, Blood. 120(22), 2012, 4432-4440. [cited by applicant]
Anonymous , “UPI000511D809”, Retrieved from the Internet Mar. 7, 2019, <https://www.uniprot.org/uniparc/UPI000 511D809>, Oct. 2014. [cited by applicant]
Belisário , et al., “Association between ENPP1 K173Q and stroke in a newborn cohort of 395 Brazilian children with sickle cell anemia”, Blood. 126(10), 2015, 1259-1260. [cited by applicant]
Buckley , et al., “Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location”, J Biol Chem. 265(29), Oct. 1990, 17506-17511. [cited by applicant]
Caballero , et al., “Impaired urinary osteopontin excretion in Npt2a-/- mice”, Am J Physiol Renal Physiol. 312(1), 2017, F77-F83. [cited by applicant]
Calvert , et al., “The Provisional Patent Application: What You Need to Know”, Inventors Eye. United States Patent and Trademark Office, Apr. 2010, 5 pages. [cited by applicant]
Cimpean , et al., “Substrate-specifying determinants of the nucleotide pyrophosphatases/phosphodiesterases NPP1 and NPP2”, Biochem J. 381(Pt 1), 2004, 71-77. [cited by applicant]
Dasgupta , et al., “Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis”, J Am Soc Nephrol. 25(10), 2014, 2366-2375. [cited by applicant]
Eller , et al., “Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure”, Nephrol Dial Transplant. 23(1), 2008, 321-327. [cited by applicant]
Flanagan , et al., “Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia”, Blood. 121(16), 2013, 3237-3245. [cited by applicant]
Fleisch , et al., “Inhibitors and promoters of stone formation”, Kidney Int. 13(5), 1978, 361-371. [cited by applicant]
Gijsbers , et al., “Functional characterization of the non-catalytic ectodomains of the nucleotide pyrophosphatase/phosphodiesterase NPP1”, Biochem J. 371(Pt 2), Apr. 15, 2003, 321-330. [cited by applicant]
Goding , et al., “Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family”, Biochim Biophys Acta. 1638(1), 2003, 1-19. [cited by applicant]
Guo , et al., “Clinical outcomes of various continued antiplatelet therapies in patients who were administered DAPT following the implantation of drug-eluting stents and developed gastrointestinal hemorrhage”, Exp Ther … [cited by applicant]
Jansen , et al., “ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release”, Proc Natl Acad Sci U S A. 110(50), 2013, 20206-20211. [cited by applicant]
Jansen , et al., “ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report”, Arterioscler Thromb Vasc Biol. 34(9), 201… [cited by applicant]
Jansen , et al., “Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D”, J Cell Sci. 118(Pt 14), 2005, 3081-3089. [cited by applicant]
Jansen , et al., “Structure of NPP1, an ectonucleotide pyrophosphatase/phosphodiesterase involved in tissue calcification”, Structure. 20(11), 2012, 1948-1959. [cited by applicant]
Jin-Hua , et al., “Molecular Coning and Chromosomal Localization of Pd-Iβ (PDNP3), a New Member of the Human Phosphodiesterase I Genes”, Genomics 45, 1997, 412-415. [cited by applicant]
Johnson , et al., “Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes”, Arthritis Rheum. 42(9), 1999, 1986-1997. [cited by applicant]
Johnson , et al., “Kabat database and its applications: 30 years after the first variability plot”, Nucleic Acids Res. 28 (1), Jan. 2000, 214-218. [cited by applicant]
Johnson , et al., “Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression”, J Bone Miner Res. 18(6), 2003, 994-1004. [cited by applicant]
Johnson , et al., “Matrix vesicle plasma cell membrane glycoprotein-1 regulates mineralization by murine osteoblastic MC3T3 cells”, J Bone Miner Res. 14(6), Jun. 1999, 883-892. [cited by applicant]
Johnson , et al., “The Nucleoside Triphosphate Pyrophosphohydrolase Isozyme PC-1 Directly Promotes Cartilage Calcification Through Chondrocyte Apoptosis and Increased Calcium Precipitation by Mineralizing Vesicles”, The… [cited by applicant]
Kato , et al., “Crystal structure of Enpp1, an extracellular glycoprotein involved in bone mineralization and insulin signaling”, Proc Natl Acad Sci U S A. 109(42), Oct. 2012, 16876-16881. [cited by applicant]
Lee , et al., “Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells”, Biochem Biophys Res Commun. 218(3, 1996, 714-719. [cited by applicant]
Li , et al., “Inhibition of Tissue-Nonspecific Alkaline Phosphatase Attenuates Ectopic Mineralization in the Abcc6 -/- Mouse Model of PXE but Not in the Enpp1 Mutant Mouse Models of GACI”, J Invest Dermatol. 139(2), Feb… [cited by applicant]
Li , et al., “Response of Npt2a knockout mice to dietary calcium and phosphorus”, PLoS One. 12(4), 2017, e0176232. [cited by applicant]
Lieben , et al., “Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization”, J Clin Invest. 122(5), 2012, 1803-1805. [cited by applicant]
Millán , et al., “Enzyme replacement therapy for murine hypophosphatasia”, J Bone Miner Res. 23(6), Jun. 2008, 777-787. [cited by applicant]
Okawa , et al., “Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine”, Nat Genet. 19(3), Jul. 1998, 271-273. [cited by applicant]
Ratkalkar , et al., “Mechanisms of Stone Formation”, Clin Rev Bone Miner Metab. 9(3-4), 2011, 187-197. [cited by applicant]
Schetter , et al., “Nucleoporins NPP-1, NPP-3, NPP-4, NPP-11 and NPP-13 are required for proper spindle prientation in C. elegans”, Dev Biol. 289(2), Jan. 15, 2006, 360-371. [cited by applicant]
Shankar , et al., “Progeria—A Brief Review”, International Journal of Pharma and Bio Sciences 2, 2010, 1-14. [cited by applicant]
Zhang , et al., “The interaction of cationic polymers and their bisphosphonate derivatives with hydroxyapatite”, Macromol Biosci. 7(5), May 10, 2007, 656-670 (Abstract Only). [cited by applicant]
Sheehan , et al., “Genetic modifiers of sickle cell anemia in the Baby Hug cohort: influence on laboratory and clinical phenotypes”, Am J Hematol. 88(7), 2013, 571-576. [cited by applicant]
Silcox , et al., “Measurement of inorganic pyrophosphate in biological fluids. Elevated levels in some patients with osteoarthritis, pseudogout, acromegaly, and uremia”, J Clin Invest. 52(8), Aug. 1973, 1863-1870. [cited by applicant]
Stefan , et al., “NPP-type ectophosphodiesterases: unity in diversity.”, Trends Biochem Sci. 30(10), Oct. 2005, 542-550. [cited by applicant]
Terkeltaub , “Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification.”, Purinergic Signal. 2(2), Jun. 2, 2006, 371-377. [cited by applicant]
Tsai , et al., “The Ectoenzyme E-NPP3 Negatively Regulates ATP-Dependent Chronic Allergic Responses by Basophils and Mast Cells”, Immunity 42, Feb. 2015, 279-293. [cited by applicant]
Van Meeteren , et al., “Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate”, J Biol Chem. 280(22), Jun. 2005, 21155-21161. [cited by applicant]
Whisstock , et al., “Prediction of proteinfunction fromprotein sequence and structure”, Quarterly Reviews of Biophysics 36, 3 (2003), pp. 2003, 307-340. [cited by applicant]
Witkowski , et al., “Conversion of a Beta-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine With Glutamine”, Biochemistry 38(36), Sep. 1999, 11643-11650. [cited by applicant]
Sayer “Progress in understanding the genetics of calcium-containing nephrolithiasis.” Journal of the American Society of Nephrology 28.3 (2017): 748-759. [cited by applicant]
Robbie, et al. “A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.” Antimicrobial agents and chemotherapy 57.12 (2013): 6147-6153. [cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/US2019/049243 issued Jan. 21, 2020. [cited by applicant]
Supplementary European Search Report for European Patent Application No. 19855284.6 dated Apr. 21, 2022. [cited by applicant]
Yin, et al. “Glycoengineering of Chinese hamster ovary cells for enhanced erythropoietin N-glycan branching and sialylation.” Biotechnology and bioengineering 112.11 (2015): 2343-2351. [cited by applicant]
Rath, et al. “Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.” Critical reviews in biotechnology 35.2 (2015): 235-254. [cited by applicant]
Dall'Acqua, et al. “Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.” The Journal of Immunology 169.9 (2002): 5171-5180. [cited by applicant]